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Abstract
Background: Virgin olive oil, a recognized healthy food, cannot be consumed in great quantities. We aim to assess
in humans whether an optimized virgin olive oil with high phenolic content (OVOO, 429 mg/Kg) and a functional
one (FOO), both rich in phenolic compounds (429 mg/Kg) and triterpenic acids (389 mg/kg), could provide health
benefits additional to those supplied a by a standard virgin olive oil (VOO).
Methods/design: A randomized, double-blind, crossover, controlled study will be conducted. Healthy volunteers
(aged 20 to 50) will be randomized into one of three groups of daily raw olive oil consumption: VOO, OVOO, and
FOO (30 mL/d). Olive oils will be administered over 3-week periods preceded by 2-week washout ones. The main
outcomes will be markers of lipid and DNA oxidation, inflammation, and vascular damage. A bioavailability and
dose-response study will be nested within this sustained- consumption one. It will be made up of 18 volunteers
and be performed at two stages after a single dose of each olive oil. Endothelial function and nitric oxide will be
assessed at baseline and at 4 h and 6 h after olive oil single dose ingestion.
Discussion: For the first time the NUTRAOLEUM Study will provide first level evidence on the health benefits
in vivo in humans of olive oil triterpenes (oleanolic and maslinic acid) in addition to their bioavailability and
disposition.
Trial registration: The Trial has been registered in ClinicalTrials.gov ID: NCT02520739.
Keywords: Olive oil, Virgin olive oil, Functional olive oil, Olive oil polyphenols, Maslinic acid, Oleanolic acid
Background
In human randomized and controlled studies olive oil,
particularly the virgin one, rich in phenolic compounds,
has been shown to provide benefits on key processes for
atherosclerosis development such as oxidative damage,
inflammation, cell adhesion molecules, and endothelial
dysfunction. In addition, a protection for hard primary
endpoints such as atrial fibrillation and diabetes by
virgin olive oil consumption has also been reported [1].
Olive oil (OO), besides its high content of a healthy fat,
the monounsaturated oleic acid, has minor components
with bioactive properties classified as: 1) the unsaponifi-
able fraction, which is extracted with solvents after OO
saponification, and 2) the soluble fraction which includes
the phenolic compounds [1]. The content of the phenolic
compounds (also known as polyphenols, when they are
the complex ones) of an OO depends of the cultivar,
climate, olive variety and ripeness, and the type of
processing. Virgin olive oil (VOO) obtained from the first
press or centrifugation of the olives has the highest
phenolic content [1]. On November 2011, the European
Food Safety Authority (EFSA) released a claim concerning
the benefits of the daily ingestion of OOs rich in phenolic
compounds on low-density lipoproteins (LDL) oxidation
[2], a known factor for coronary heart disease develop-
ment. The use of the claim in OO bottles, is regulated in
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the Commission Regulation (EU) N° 432/2012 [3] as: “The
claim may be used only for OO which contains at least
5 mg of hydroxytyrosol and its derivatives (e.g. oleuropein
complex and tyrosol) per 20 g of olive oil. This implies
that only high phenolic content OOs can bear the claim.
Due to this, the need to optimize the OO processing in
order to obtain high phenolic content OOs is one of the
current goals in terms of increasing the nutritional value
of an olive oil.
Among minor OO components triterpenic acids from
the OO unsaponifiable fraction have also potential
benefits for health. The seeds and the skin of the olives,
used to produce pomace olive oil, are very rich in triter-
penic acids. Pomace olive oil and oleanolic and maslinic
acids, have shown to have bioactive properties in cellular
and animal models [4–6]. The human health benefits of
triterpenes from olive oil have not been at present
evaluated. We hypothesized that an optimized VOO
with a high phenolic content (OVOO) and a functional
olive oil (FOO) rich in both phenolic compounds and
triterpenic acids can provide additional benefits, to those
provided by an standard VOO, on risk factors for coron-
ary heart disease (CHD) in humans. We are also aimed
to assess the bioavailability and disposition of oleanolic
and maslinic acids in humans, a key point for supporting
the rationale of their health benefits.
According to the Evidence Based Medicine [7], the
healthy properties of OVOO and FOO must be tested in
proper clinical randomized trials, versus VOO obtained
by traditional procedures, for ensuring that their benefits
for health are really highlighted.
Method/design
Aim of the study
The objectives of the present trial are on one hand to
assess the benefits of the enrichment of VOO with both
olive oil polyphenols and triterpenes on lipid and DNA
oxidation, inflammation, and endothelial function in
healthy volunteers. On the other hand, the study is
aimed to assess the bioavailability of oleanolic and masli-
nic acids from olive oil in humans.
The primary null hypothesis is: The efficacy for
protecting against lipid and DNA oxidation, inflamma-
tion, and endothelial dysfunction of the olive oils will be
as follows: FVOO >OVOO >VOO.
In order to be able to obtain future health claims from
EFSA or FDA for the functional OOs we will also
examine the bioavailability in humans of their active
principles (phenolic compounds and triterpenes such as
oleanolic and maslinic acids), and its time-and-season
variability. Our primary null hypothesis is that the
biovailability of triterpenes in humans will be dose-
dependent of the triterpenic content of the olive oils.
Characteristics of the olive oils
Olive oils will be specially prepared for the trial from an
extra virgin olive oil (VOO), produced from Picual olives
(Andalucía, Spain). They will have similar fat and micro-
nutrient, (i.e vitamin E, sitosterols, etc..) composition
with exception of their phenolic/triterpene content. A
VOO obtained by a traditional procedure will be used as
a control. An optimized virgin olive oil (OVOO) will be
obtained by mixing the best olive oils from several olive
varieties with very high phenolic content and by using
optimized extraction procedures. A functional olive oil
(FOO), rich in both high phenolic compounds and
triterpenes, will be obtained by addition to the OVOO
of an extract of oleanolic and maslinic acids obtained
from olive skin by physical procedures. Characteristics
of the olive oils to be used in the study (pilot data) are
shown in Table 1.
Design
The study is a randomized, double-blind, crossover,
controlled, and double-center trial. The trial was conducted
in Virgen de las Nieves and San Cecilio General Hospitals
of Granada, Spain. The trial comprises a sustained
consumption study and, nested within, a dose-response
study in which the bioavailability of active principles,
phenolic compounds and triterpenes will be assessed. After
6-months, the bioavailability study will be repeated in order
to assess time-and-season variations in the bioavailability of
the active principles. The study will be sequentially con-
ducted as follows: enrollment after screening via inclusion
and exclusion criteria, randomization, treatment periods,
and assessment.
The protocol will be conducted in accordance with the
Declaration of Helsinki and the Good Clinical Practice
Guidelines [8]. All investigators are appropriately quali-
fied to conduct and supervise the trial. All patients will
provide written informed consent prior to study entry.
The flow chart of this study is shown in Fig. 1.
Participants and eligibility
Inclusion criteria
Individuals aged from 20 to 60, healthy on the basis of
physical examination and routine biochemical and
hematological laboratory determinations, with willing-
ness to provide written informed consent and to adhere
to the protocol.
Exclusion criteria
Smoking, intake of antioxidant supplements, aspirin, or
any other drug with established antioxidant properties,
hyperlipidemia, obesity (body mass index >30 kg/m2),
diabetes, hypertension, celiac or other intestinal disease,
any condition limiting mobility, life-threatening diseases,
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or any other disease or condition that would impair
compliance.
Recruitment
Participants will be recruited from the general popula-
tion of Granada, Spain, by using newspaper and tableaux
advertisements in civic centers. A total of fifty-four
individuals (27 males and 27 women) are expected to be
recruited in this trial.
Randomization and allocation concealment
Using a stratified block randomization method, the eligible
patients will be randomly allocated to three sequences of
olive oil administration. Random numbers will be generated
by a computerized random-number generator using the
block-randomization method of a software program for
sequence generation by an independent statistician. The
randomization lists will be concealed in a lightproof sealed
envelope. The sealed envelopes will be kept by the inde-
pendent statistician of the study. Participants, investigators,
and outcome assessors will be blinded to the treatment
allocation throughout the course of the study.
Blinding and code breaking
Olive oils will be coded, providing masking to the treat-
ment assignment to ensure double blinding. Participants,
clinicians, technicians, outcome assessors, and investiga-
tors will be unaware of the sequence group assignments
or block size. If a participant has a serious adverse event
and an immediate cessation of trial treatment is re-
quired, the blinding code will be broken. Daily doses of
olive oil will be prepared in special containers with the
three types of olive oil labeled “A”,“B”, and “C”. Con-
tainers with the corresponding 30 mL olive oil daily dose
will be delivered at the beginning of each intervention
period to the participants.
Intervention
Participants will be randomly assigned to three se-
quences of olive oil administration. Olive oils (VOO,
OVOO, and FOO) will be sequentially administered over
three periods of 3 weeks preceded by 2-week washout
periods in which participants will be requested to avoid
olives and olive oil consumption. During olive oil inter-
vention periods participants will be requested to ingest a
raw daily dose of 30 mL of olive oil distributed over
three meals. During washout periods participants will be
provided of sunflower olive oil for raw and cooking
purposes. Details of the sustained consumption study
procedures are shown in Table 2. For participants
entering in the dose-response bioavailability study at the
beginning of each intervention period the corresponding
30 mL daily dose of olive oil (VOO, OVOO, or FOO)
will be administered as a single dose at fasting state.
After 6 months the bioavailability study will be repeated
to assess time-and-season variations. Details of the bio-
availability study procedures are shown in Table 3.
Table 1 Characteristics of the olive oils to be used in the
NUTRAOLEUM Study
Component VOO OVOO FOO
Free acidity (% of oleic acid) 0.13 0.12 0.13
Peroxide value, (meq O2/kg oil) 6.9 7.7 9.1
K270 0.11 0.12 0.12
K232 1.42 1.35 1.43
Esqualene (mg/100 g) 529 536 545
Fatty acids (%)
Palmitic 10.0 10.4 10.2
Palmitoleic 0.4 0.6 0.6
Estearic 2.3 2.2 2.1
Oleic 78.9 78.2 78.4
Linoleic 6.6 6.8 6.9
Linolenic 0.6 0.7 0.7
Arachidonic 0.4 0.4 0.4
Eicosanoic 0.3 0.4 0.4
Total phenolic compounds (ppm) 124 490 487
Hydroxytyrosol and derivates 105 424 423
Lignanes 18.2 61.3 59.2
Flavonoids 0.7 3.4 3.2
Simple phenols 0.0 0.9 0.9
Triterpenic acids (mg/kg) 86.3 86.5 389
Maslínic 47.3 47.3 218
Oleanolic 39.2 39.1 171
Sterols (ppm) 1437 1396 1460
Campesterol (%) 2.9 3.0 3.0
Stigmasterol (%) 0.7 0.7 0.8
B-Sitosterol (%) 94.2 94.2 94.6
D7-Stigmastanol(%) 0.3 0.4 0.3
Eritrodiol + Uvaol (%) 1.5 1.5 1.4
Alpha-tocopherol 183 174 176
Total carotenoids (ppm) 7.1 6.8 7.0
Beta-carotene 2.6 2.3 2.7
Lutein 3.1 3.4 3.1
Xantophyll pigments 1.3 1.1 1.2
Chlrophyll pigments 8.7 10.8 9.8
Clrophyll a + b 0.4 0.5 0.5
Pheophytyn a + b 7.7 9.6 8.8
VOO virgin olive oil, OVOO optimized virgin olive oil with a high phenolic
content, FOO funcional olive oil rich in phenolic compounds and oleanolic and
maslinic acids
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Dietary control
A three-day dietary record will be registered at the be-
ginning of the study and after each intervention period.
Energy consumption and dietary intakes of macro- and
micronutrients will be calculated from the 3-day records
using an appropriate software. To avoid an excessive in-
take of antioxidants and phenolic compounds during the
clinical trial period, participants will limit the consump-
tion of the followings foods to: 2 servings of vegetables
or pulses/day; 3 servings of fruits (including juices)/day;
3 cups of tea or coffee/day; 1 piece of a bar of chocolate
(15 g)/day; 2 glasses of wine/day; 30 g/week of nuts; fish,
with preference for the white one, to a maximum of 2
servings (150 g/serving)/week; to avoid products canned
with oils, such as sardines, peppers, etc…Participants
will be asked to avoid to take meals out of home, if
possible, and to bring with them the individual olive oil
containers for their use at meals. Participants will be
personally advised by a nutritionist on how to record
food consumption and follow the above mentioned
dietary recommendations.
In the dose-response bioavailability study, after an
overnight fast, volunteers will ingest 30 mL of one of the
three olive oils with a standard piece of bread (80 g). At
6 h and at 10 h after the olive oil ingestion participants
will receive a low-phenolic content meal or snack avoid-
ing the previously described foods. During the previous
3-days of each intervention period, participants were
requested to avoid moderate or intense physical activity.
Outcome measures
In the sustained consumption study we will assess
outcome measures at the beginning of the study, and
before and at the end of each olive oil intervention
period (Table 2). Biological samples will be collected at
fasting state of minimum 10 h, and 24-h urine will be
also collected. In the dose-response bioavailability study
blood samples and urine collection will be collected at
several times at postprandial time (Table 3). Serum and
plasma will be obtained by centrifugation of blood at
1500 g at 4 °C for 20 min and stored at − 80 °C in the
central laboratory’s biobank of Virgen de las Nieves
Hospital. Whole blood will be collected at baseline and
at 5 h after olive oil intake in PAXgene tubes for future
gene expression analyses and stored at −80 °C after 2 h
at room temperature.
Primary outcomes
Primary outcomes will be markers of lipid and DNA
oxidation, inflammation, and endothelial function. Con-
cerning DNA oxidative damage, there is evidence of its
role in various diseases, particularly in cancer, but also
in atherosclerosis. Among DNA oxidative damage bio-
markers, urinary 8-oxo-7,8-dihydro-20-deoxyguanosine
(8-oxo-dG) has received particular interest [9]. A recent
meta-analysis has established that 8-oxo-dG levels are
higher in patients with CVD than in controls [10]. DNA
repair is thought to be a major contributor to urinary
8-oxo-dG levels, diet, per se, and cell turnover playing
negligible roles [11]. However, reactive oxygen species
(ROS) induced 8-oxo-dG can promote DNA hypome-
thylation by inhibiting DNA methylation at cytosine
bases located nearby. This ROS-induced DNA hypome-
thylation is related to both malignant transformation
and tumor progression [12]. In our experience [13–15]
and that from others [16], consumption of antioxidant-
rich foods, including olive oil, and dietary patterns, such
as the Mediterranean diet, have shown to decrease
urinary 8-oxo-dG concentrations in healthy individuals
and metabolic syndrome patients. Due to this, we
Fig. 1 Flow chart of the study. Sequence 1: a, b, and c olive oils; Sequence 2 :b,c, and a olive oils; Sequence 3: c, a, and b olive oils
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selected to assess DNA oxidative damage, through
8-oxo-dG measurement, as a primary outcome.
At the beginning of the study, and before and at the end
of each olive oil intervention period, serum glucose,
cholesterol, and triglycerides will be determined by stand-
ard enzymatic methods in a PENTRA-400 autoanalyzer
(ABX-Horiba Diagnostics, Montpellier, France). HDL chol-
esterol will be measured as a soluble HDL cholesterol
determined by an accelerator selective detergent method
(ABX-Horiba Diagnostics,Montpellier, France). LDL choles-
terol will be calculated by the Friedewald formula. Oxidized
LDL will be determined in serum by a sandwich ELISA
procedure using the murine monoclonal antibody mAB-
4E6 as capture antibody, and a peroxidase conjugated
antibody against oxidized ApoB bound to the solid phase
(ox-LDL, Mercodia AB, Uppsala, Sweden).). Conjugated
dienes in LDL will be measured spectrophotometrically at
234 nm after Cu++ oxidation. Urine total F2α-isoprostanes
(8-iso-PGF2α) and 8-oxo-dG will be determined by ELISA
(Oxford Biomedical Research, Michigan, USA, and JaICA,
Japan Institute for the Control of Ageing, Fukuroi,
Shizuoka, Japan, respectively). Specific biomarkers of in-
flammation and cardiovascular risk, including adiponectin,
resistin, myeloperoxidase (MPO), plasminogen activator
inhibitor-1 (PAI-1), tumour necrosis factor-alpha (TNF-α),
interleukin-6 (IL-6), interleukin-8 (IL-8), soluble intercellular
Table 2 Detailed study procedures in the sustained consumption study (0 mL/day, 3-week intervention periods)
Study Period
Visit (V) number
WO, washout period
IP, Intervention period
Enrollment V1
(WO)
V2
(IP 1)
V3
(WO)
V4
(IP 2)
V5
(WO)
V6
(IP 3)
V7
(Close out)
Time Point, week
(Week range)
Up to -12 0
(0–2)
2
(2–5)
5
(5–7)
7
(7–10)
10
(10–12)
12
(12–15)
15
Screening routine laboratory analyses X
Demographic/ habits information-taking X
Informed consent form X
Randomization & allocation X
Treatment distribution X X X
Blood and 24 h-urine collection at fasting X X X X X X X
Assessments
General outcomes
General medical questionnaire X X X X X X X
Alcohol consumption questionnaire X X X X
3-day dietary record X X X X
Minnesota Leisure Time Physical Activity questionnaire X X
Blood pressure and anthropometric X X X X X X X
Visual Analogue Scale X X X
Monitoring adverse effects X X X
Compliance check (containers) X X X
Primary outcomes
Plasma Lipid profile X X X X X X X
Plasma Lipid and DNA oxidation X X X X X X X
Plasma Inflammation markers X X X X X X X
Secondary outcomes
Plasma Antioxidant vitamins X X X X X X X
Plasma fatty acids X X X X X X X
Serum Endothelin X X X X X X X
Ex vivo cell immune response X X X X
Compliance markers
Urinary tyrosol and hydroxytyrosol X X X X X X X
Plasma Triterpenes X X X X X X X
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adhesion molecule-1 (sICAM-1) and soluble vascular adhe-
sion molecule-1 (sVCAM-1), will be assessed by Luminex
200 system with the XMap technology (Luminex Corpor-
ation, Austin, TX, USA) using human monoclonal anti-
bodies (Milliplex Map Kit, Millipore, Billerica, MA, USA.
Within the frame of the bioavailability study endothelial
function will be measured by peripheral arterial tonometry
with the EndoPAT 2000 device (Itamar Medical Inc.,
Caesarea, Israel), at baseline and at 4 and 6 h after the inges-
tion of the single 30 mL dose of the olive oils (Table 3).
Secondary outcomes
Systolic and diastolic blood pressures will be measured
with a mercury sphygmomanometer after a minimum of
10 min rest in the seated position; the average of two
measurements will be recorded. Physical activity, a
potential confounder variable concerning oxidative and
anti-inflammatory status will be recorded at the begin-
ning and at the end of the study, and assessed by the
Minnesota Leisure Time Physical Activity Questionnaire
validated for its use in Spanish men and women [17, 18].
A visual analogue scales (VAS) for measurement of
appetite sensations will be administered at the end of
each intervention period [19].
Tocopherol, beta-carotene, retinol, and Coenzymes Q9
and Q10 will be measured by high-pressure liquid chroma-
tography (HPLC) coupled to mass spectrometry detection
(HPLC-MS) with after extraction with 1-propanol. Plasma
fatty acids will be measured after methylation by gas-
liquid chromatography coupled to mass spectrometry
detection (GS-MS). Serum endothelin will be determined
by ELISA (R&D Systems, Minnesota, USA). After whole
blood ex vivo stimulation cultures, with challenging mole-
cules such as E.coli lipopolysacaride or a Phaseolus
Vulgaris phytohemaglutinin, an additional panel of im-
mune biomarkers: IL-1 beta, IL-2, IL-4 and interferon
gamma, among others will be measured by Luminex.
Within the frame of the bioavailability studies, nitric oxide
(spectrometry), and gastrointestinal hormones (grelihn,
amilin, gastric inhibitory polypeptide (GIP), glucagon-like
peptide-1 (GLP-1), pancreatic polypeptide (PP), polypep-
tide YY (PYY) and colecistokinine will be performed at
baseline and at 2, 4, and 6 h after the ingestion of a single
dose of the olive oils (Table 3).
Compliance markers
Tyrosol and hydroxytyrosol in urine samples [20], and
oleanolic and maslinic in plasma, will be determined by
gas chromatography-mass spectrometry (GC/MS) at the
beginning of the study and before and after intervention
periods in the sustained consumption study. Postpran-
dial kinetics of the biomarkers will be measured at the
bioavailability study (Table 3).
Withdrawal, dropout, discontinuation and compliance
Participants will be allowed to withdraw at any time
during this clinical trial. Participants who withdraw will
be followed to investigate the reason for withdrawal.
Table 3 Detailed study procedures in the bioavailability study (30 mL single dose)
Visit (V) number
IP, Intervention period
Enrolment V2
(IP 1)
V4
(IP 2)
V6
(IP 3)
Time Point, week Up to -12 2 7 12
Informed consent form X
Randomization & allocation X
Treatment distribution X X X
Blood collection at baseline (0 h) and at 30 min, 45 min,
1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, and 24 h after oils ingestion
X X X
Urine collection at baseline (0 h) and at
0–2 h, 2–4 h, 4–6 h, 6–8 h, 8–10 h, 10–12 h, 12–24 h,
after oils ingestion
X X X
Assessments
Primary outcomes
Urinary tyrosol and hydroxytyrosol at 0–2 h, 2–4 h, 4–6 h,
6–8 h, 8–10 h, 10–12 h, 12–24 h, after oils ingestion
X X X
Plasma Triterpenes at baseline (0 h) and at 30 min, 45 min,
1 h, 2 h, 4 h, 6 h, 8 h, 10 h, 12 h, and 24 h after oils ingestion
X X X
Endothelial function measurements at baseline (0 h) and at
4 h, and 6 h, after oils ingestion
X X X
Secondary outcomes
Plasma gastrointestinal hormones t baseline (0 h) and at 2 h,
4 h, and 6 h, after oils ingestion
X X X
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Participants may be advised to discontinue this trial if
there is a serious intervention related adverse event or if
the participant is noncompliant with the study proced-
ure. Participants will be instructed to return the individ-
ual olive oil containers when collecting the next daily
doses for the amount of unconsumed olive oil to be
registered. Participants whose compliance with treat-
ments or placebo is ≤ 80 % of the total will be considered
to have dropped out.
Standard operation procedures for quality assurance
We have established detailed standard operating proce-
dures for this clinical trial and have educated all practi-
tioners, nurses, and technicians and set qualification
standards to make sure the patients are treated with high
standards and in accordance with the trial protocol.
Practitioners and medical personnel will attend a 2-day
training workshop about the trial procedures, and be
aware of any change in the protocol. A written protocol
and standardized recording documents will be provided.
All personnel involved in the study, will be blinded to
group allocations. A First Entry Data Monitoring and a
Field Control Quality Visit at the middle of the study
will be performed by external audit (NUPROAS HB)
which is independent from field work investigators and
the sponsor.
Adverse events and safety monitoring
Although the treatments are natural foods, olive oils, all
unexpected adverse events related to the interventions
will be reported to the investigators by participants and
written on the individual case report form by the investi-
gator. Each participant will be monitored for adverse
events (pain at acne lesions or other sites, nausea/vomit-
ing, fatigue, allergic reaction, and any adverse events
related to intervention) after each visit.
Sample size and power analysis
Accepting an alpha risk of 0.05 and a beta risk of 0.20 in
a two-sided test, at least 40 subjects in the sustained
consumption study are necessary to recognize as statisti-
cally significant a difference greater than or equal to 10
units in the oxidized LDL. A dropout rate of 15 % was
anticipated. This sample size will also permit to show, as
statistically significant with a power of 80 %, a difference
of 10 lag-time units among treatments in the clinical
trial. Drop-outs before the first intervention period will
be replaced in order to avoid drop-outs greater than
15 %. We will enlarge the sample size to 54 in order to
have more statistical power for our results.
Statistical analyses
Normality of variables will be assessed by normal prob-
ability plots. One-factor ANOVA or Kruskal-Wallis test
will be used to determine differences in basal character-
istics and nutrient intake among the three olive oil inter-
ventions as appropriate. Period and sequence effects
concerning a carryover effect will be assessed by means
of an Analysis of Variance for repeated measures. The
possible carryover effect will be corrected by the adjust-
ment of final values after intervention periods by the values
at the corresponding baseline period for each intervention.
A general linear model for repeated measurements, with
Tukey’s correction for multiple comparisons, will be fitted
in order to assess differences between values at the
beginning and at the end of each intervention period, and
at postprandial state. Linear regression models will be used
to adjust values at the end of the intervention periods for
basal values in order to assess the linear trend across
interventions. The paired comparison of post-intervention
target concentrations will be carried out by a General
Linear Mixed Model (GLMM) with the olive oil type
(VOO, OHPCO, FOO) as fixed factor; individual level of
test subjects as random effect; and, basal values for each
intervention period, olive oil administration order, and age.
Statistical significance was defined as P < 0.05 for a
two-sided test. These statistical analyses will be performed
using IBM SPSS Statistics 19.
Discussion
The NUTRAOLEUM Study is designed to assess whether,
besides an increase in the polyphenol content of the olive
oil (OVOO), and additional enrichment of this OVOO with
oleanolic and maslinic acids from olive seeds (Functional
OO, FOO) will increase the healthy benefits of these OOs
versus an standard VOO. The benefits of rich-phenolic
natural OOs on risk factors for chronic diseases have been
established in human studies Diet [1]. Within the PRE-
DIMED (Prevención por Dieta Mediterránea) Study we ob-
served a decrease in the atrial fibrillation in cardiovascular
disease risk individuals (n = 7440) when the Mediterranean
diet was supplemented with extra-VOO [21]. The EUROL-
IVE Study was a randomized, crossover, controlled study
with 200 European healthy volunteers, and three similar
OOs but with differences in their phenolic content (from
2.7 to 360 ppm) [22]. From our EUROLIVE results an
increase in HDL cholesterol and a decrease in the oxidative
damage to lipids, including the in vivo oxidized LDL a
recognized biomarker for CHD [23], in a dose-dependent
manner of the phenolic content of the OO administered
were observed. Recently in a subsample of the EUROLIVE
study we have reported: 1) an increase of the HDL
functionality, evidenced by an increase in the cholesterol
efflux from cells, linked to the high-phenolic content OO
versus the low content one [24]; and 2) a decrease in total
and small LDL particles [25]. Total LDL particles (LDL-P)
is now considered to be a biomarker for CHD with the
same or higher predictive power than LDL cholesterol [26].
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Benefits of high phenolic VOO consumption on other
risk factors particularly inflammation, endothelial func-
tion and thrombosis markers have also been reported
in vivo in humans, including a nutrigenomic effect
modulating atherosclerosis-related genes towards a pro-
tective mode [1, 27]. In front of other edible oils, VOO
reduced the postprandial endoplasmic reticulum stress in
obese people [28].
In our experience, functional olive oils enriched with
phenolic compounds provide more health benefits than
the parental VOOs. A functional olive oil enriched with
its phenolics (990 ppm), when comparing with the
parental VOO (200 ppm of phenolic compounds), was
able to reduce the endothelial dysfunction [29] and to
enhance the expression of cholesterol efflux related
genes in vivo in pre- and stage 1 hypertensive patients
[30]. Within the VOHF (Virgin Olive oil and HDL Func-
tionality) Study we have recently reported that a func-
tional olive oil enriched with OO phenolics (500 ppm)
and with them and those of thyme (500 ppm equimolar)
improved the lipoprotein particle subclasses distribution
and their associated atherogenic ratios [31, 32]. The
functional OOs used in the studies referred to above
were enriched from isolated OO phenolic extracts. In
the NUTRAOLEOUM study, however, a “coupage” of
natural olive varieties together with selected extraction
procedures were used for making the OVOO. Besides a
more equilibrate micro-nutrient composition, the or-
ganoleptic characteristic profile, corresponding to a
natural VOO, is expected to enhance the consumers
acceptation of the NUTRAOLEOUM OOVO.
The NUTRAOLEUM Study will also evidence for the
first time whether the OO triterpenes can provide
benefits for human health. Despite a large body of
experimental data reporting bioactive effects [4–6], at
present, and to the best of our knowledge, no human
randomized controlled trial for assessing the in vivo
potential benefits in humans of oleanolic and maslinic
acid from olive oil has been undertaken. We are aimed
to take the challenge on the issue in order to provide
first level evidence whether triterpenes from olive oil
have, or have not, bioactivity in vivo in humans. Data on
the bioavailability of oleanolic and maslinic acid in
humans are scarce. The NUTRAOLEUM Study will
provide for the first time information from a randomized
controlled trial on the bioavailability and disposition in
humans of the oleanolic and maslinic acids present in
OOs. Olive oil, a recognized healthy food, can not be
consumed in great quantities. Due to this, an increase in
the OO bioactive components, such as triterpenes (i.e.
FOO) and phenolic compounds (i.e. both FOO and
OVOO) is a way for enhancing OO health-promoting
properties whilst consuming the same or less fat.
Currently, functional foods are developed to improve the
properties of natural food components. However, func-
tional foods must be tested in human clinical interven-
tion trials with an appropriate design. Consumers are
more and more frequently asking for an “added value” in
the nutritional properties of the food to be purchased.
Thus, answers from the Olive Oil Industry and from
researchers, concerning functional olive oils with tested
healthy properties are needed.
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